Abstract
Clavulanic acid is an inhibitor of certain beta-lactamases, notably those enzymes which inactivate the penicillins and cause resistance of important bacteria to these antibiotics. Microbiological, pharmacological, and clinical studies show that clavulanic acid in combination with amoxycillin is effective and safe in the treatment of urinary-tract infection caused by amoxycillin-resistant bacteria.
Publication types
-
Clinical Trial
-
Controlled Clinical Trial
MeSH terms
-
Administration, Oral
-
Amoxicillin / administration & dosage*
-
Bacteriuria / microbiology
-
Biological Products / administration & dosage*
-
Carboxylic Acids / administration & dosage*
-
Clavulanic Acid
-
Clinical Trials as Topic
-
Drug Combinations
-
Enterobacteriaceae / drug effects
-
Enterobacteriaceae Infections / drug therapy*
-
Enterobacteriaceae Infections / microbiology
-
Enzyme Inhibitors / administration & dosage*
-
Humans
-
Penicillin Resistance
-
Staphylococcal Infections / drug therapy
-
Staphylococcal Infections / microbiology
-
Staphylococcus aureus / drug effects
-
Streptomyces*
-
Tablets
-
Urinary Tract Infections / drug therapy*
-
beta-Lactamase Inhibitors*
-
beta-Lactams / administration & dosage
Substances
-
Biological Products
-
Carboxylic Acids
-
Drug Combinations
-
Enzyme Inhibitors
-
Tablets
-
beta-Lactamase Inhibitors
-
beta-Lactams
-
Clavulanic Acid
-
Amoxicillin